

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 9/3/1974  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Cystic Fibrosis (CFTR) Sequencing (Temporary Referral as of 12/07/20)**

ARUP test code 0051110

CF CFTR Specimen whole Blood

Cystic Fibrosis (CFTR) Sequencing

Negative

TEST PERFORMED - 0051110  
TEST DESCRIPTION - Cystic Fibrosis (CFTR) Sequencing  
INDICATION FOR TEST - Confirm Diagnosis

RESULT  
No pathogenic variants were detected in the CFTR gene.

INTERPRETATION  
No pathogenic variants were detected in the CFTR gene using bidirectional sequencing of the coding regions and intron-exon boundaries. Sequencing detects 97 percent of CFTR variants, thus, the risk for cystic fibrosis (CF) or CF carrier status is reduced.

RECOMMENDATIONS  
Medical management should rely on clinical findings and family history. According to information provided to ARUP, this individual has pancreatitis. Variants in the CTRC, SPINK1, and PRSS1 genes are also associated with hereditary pancreatitis. If strong clinical concern for hereditary pancreatitis remains, sequencing of the SPINK1 and CTRC genes, and full gene analysis of the PRSS1 gene (ARUP test codes 2002012, 2010703, and 3001768, respectively) should be considered. Genetic consultation is indicated.

COMMENTS  
Reference Sequence: GenBank # NM\_000492.3 (CFTR)  
Nucleotide numbering begins at the "A" of the ATG initiation codon.  
Likely benign and benign variants are not reported.

This result has been reviewed and approved by [REDACTED]

H=High, L=Low, \*=Abnormal, C=Critical

**BACKGROUND INFORMATION: Cystic Fibrosis (CFTR) Sequencing**

**CHARACTERISTICS:** Chronic sino-pulmonary disease, gastrointestinal malabsorption/pancreatic insufficiency, and obstructive azoospermia. Findings are often limited to a single organ system such as isolated pancreatitis, bilateral absence of the vas deferens, nasal polyposis, or bronchiectasis in non-classic cystic fibrosis (CF).  
**INCIDENCE OF CLASSIC CF:** 1 in 3,000 Caucasians or Ashkenazi Jewish, 1 in 8,000 Hispanics, 1 in 15,000 African Americans, 1 in 32,000 Asians.  
**INCIDENCE OF NONCLASSIC CF:** Unknown.  
**INHERITANCE:** Autosomal recessive.  
**PENETRANCE:** High for severe mutations, variable for mild/moderate mutations.  
**CAUSE OF CLASSIC CF:** Two deleterious CFTR mutations on opposite chromosomes.  
**CAUSE OF NONCLASSIC CF:** Typically one severe and one mild/moderate CFTR mutations on opposite chromosomes.  
**CLINICAL SENSITIVITY:** 97 percent.  
**METHODOLOGY:** Bidirectional sequencing of the entire CFTR coding region, intron-exon boundaries, and two deep intronic mutations.  
**ANALYTICAL SENSITIVITY AND SPECIFICITY:** 99 percent.  
**LIMITATIONS:** Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations, large gene deletions/duplications and some deep intronic mutations will not be detected.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement C: aruplab.com/CS

**VERIFIED/REPORTED DATES**

Procedure	Accession	Collected	Received	Verified/Reported
CF CFTR Specimen	20-318-401249	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Cystic Fibrosis (CFTR) Sequencing	20-318-401249	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

**END OF CHART**

**H=High, L=Low, \*=Abnormal, C=Critical**